首页> 外文期刊>International Journal of Biotechnology and Biomedical Sciences: IJBBS >Factors Affecting Affordability and Accessibility of Cardiovascular Healthcare in India
【24h】

Factors Affecting Affordability and Accessibility of Cardiovascular Healthcare in India

机译:影响印度心血管医疗保健的负担能力的因素

获取原文
获取外文期刊封面目录资料

摘要

Background: India bears the greatest burden of cardiovascular diseases (CVDs). The key issues of CVDs healthcare management are poor access to medical treatment, high mortality rate, prevalence in rural India, out-of-pocket expenditure, increasing poverty, loss of productivity and widening inequality in care. Method: By using purposive sampling, we conducted semi structured interviews with some prominent authorities, scientists, cardiologists, policy experts and IP experts engaged in R&D on CVDs and public health. Some important databases are also used for literature review and for detailed study and analysis of research priorities in CVDs India. Results: Various significant factors are emerged from the analysis. First, government should enforce certain regulatory mechanisms on private sector to make price of drugs/diagnostics affordable and uniform. Second, strict implementation of selling drugs with generics names rather than branded is required. Third, India needs indigenous R&D in medical technology that work within the constraints of our system, understanding the local context. Fourth, government will need to strict their Intellectual property (IP) rules for possible far reaching implication on CVDs or NCDs drug access and development. Other than this, Patient education level and disease awareness is also influence the access of CVDs treatment. Conclusion: The early occurrence of CVDs is minacious and deserves specific actions. Though interviewees suggested that regulation of private sector with good governance is possibly the solution to provide proper access to medicines and also recommends public private partnership (PPP) to provide better coordination between S&T activities for indigenous and affordable CVDs product development. The analysis also propose that disease specific government policy are highly required in India.
机译:背景:印度承担了最大的心血管疾病(CVDS)负担。 CVDS医疗保健管理的关键问题较差的医疗,高死亡率,农村患病率,新的支出,增加贫困,生产力丧失和扩大护理的不平等。方法:通过采用目的地采样,我们与一些着名的当局,科学家,心脏病学家,政策专家和知识产权专家进行了半结构化访谈,从事R& d在CVDS和公共卫生。一些重要数据库也用于文献综述以及CVDS印度研究优先事项的详细研究和分析。结果:从分析中出现了各种重要因素。首先,政府应对私营部门执行一定的监管机制,以销售药物/诊断价格实惠和制服。其次,需要严格执行销售普通名称而不是品牌的销售药物。第三,印度需要土着R& D在医疗技术中,在我们的系统的限制范围内工作,了解当地背景。第四,政府需要严格严格对CVDS或NCDS药物访问和发展造成的影响。除此之外,患者教育水平和疾病意识也会影响CVDS治疗的访问。结论:早期发生的CVDS是盲目的,值得具体的行动。虽然受访者建议具有良好治理的私营部门的监管可能是提供适当获取药物的解决方案,并建议公共私人伙伴关系(PPP)在S& T活动之间提供更好的土着和实惠的CVDS产品开发活动。该分析还提出了印度的疾病特定的政府政策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号